Key result
Acute selective endothelin-A receptor antagonism with BQ-123 significantly reduced mean arterial pressure, proteinuria, and pulse wave velocity compared to placebo in chronic kidney disease.
Why the study?
Does acute selective endothelin-A receptor antagonism with BQ-123 improve surrogate markers of cardiovascular risk in patients with nondiabetic chronic kidney disease?
Population
22 subjects with proteinuric nondiabetic chronic kidney disease
Comparison
Selective endothelin-A receptor antagonism with… vs Placebo; a subset of 10 subjects also received…
Design
RCT, randomized crossover, double-blind
Follow-up
acute (monitored after drug dosing)
Authors
Loading...
Acute ET-A antagonism improves CV risk surrogates in nondiabetic CKD; extends randomized evidence and supports longer-term outcome trials.
RCT (n=22)
Double-blind
crossover
Does acute selective endothelin-A receptor antagonism with BQ-123 improve surrogate markers of cardiovascular risk in patients with nondiabetic chronic kidney disease?
p-value: p=<0.001
Acute endothelin-A receptor antagonism with BQ-123 reduces proteinuria and arterial stiffness in nondiabetic CKD patients independently of its blood pressure-lowering effects.
Dhaun et al. (2009) conducted an RCT in nondiabetic chronic kidney disease (n=22). BQ-123 vs. Placebo and nifedipine was evaluated on Blood pressure, proteinuria, renal hemodynamics, arterial stiffness, and endothelial function (p=<0.001). Acute selective endothelin-A receptor antagonism with BQ-123 significantly reduced mean arterial pressure, proteinuria, and pulse wave velocity compared to placebo in chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: